As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive) metastatic…
With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive) metastatic…
Chronic myeloid leukemia (CML) in China presents a huge challenge for healthcare providers but is a considerable opportunity for drug manufacturers. The launch of Novartis’s Glivec (imatinib), an…
The rising cost of healthcare is a global theme. As multinational pharmaceutical companies shift their focus from mature Western markets to the emerging Asian markets, it is vital to understand the…
Physicians Would Welcome Therapies Causing Lower Rate of Serious Infections than Remicade, but Will Payers View Such Agents Favorably? Treatment for Crohn’s disease (CD)—a relapsing/remitting…
Physicians Would Welcome Therapies Causing Lower Rate of Serious Infections than Remicade, but Will Payers View Such Agents Favorably? Treatment for Crohn’s disease (CD)—a relapsing/remitting…
Asthma is a chronic inflammatory disorder of the airways leading to recurring episodes of wheezing, breathlessness, chest tightness, and coughing, with episodes characterized by airflow obstruction…
Serious Gram-negative (GN) pathogens are clinically-important pathogens in both the hospital and outpatient settings. GN pathogens are often acquired in healthcare facilities, and therefore have a…
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the seventh most common type of cancer worldwide and the second most common cause of cancer death worldwide. Most risk…
What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…
What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…
What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…
The hospital-treated methicillin-resistant Staphylococcus aureus (MRSA) infection market is dominated by generic vancomycin because of its low cost, physician familiarity and relatively high…
Amid the Emergence of a Novel Class of Dual Bronchodilators, What Are the Key Areas of Opportunity for Differentiation According to Pulmonologists and Payers? Treatment of chronic obstructive…